ALK Positive Australia Inc.

We have a Patient Information Guide that is downloadable on our website, that provides an excellent overview of ALK+ cancer & the treatments available to us in Australia. alkpositive.org.au/patient/

The '4' in Laces4Lungs represents both AJ's age - 4 months old - and the stage of his Mums ALK+ lung cancer, at diagnosis. What a powerful fundraising drive this has become.
Order your laces today: docs.google.com/document/d/e...

This Lung Cancer Awareness Month, Bec & Chris Henry are pedalling 620km over 5 days, visiting every PET scan centre in WA.

Their goal? To raise $10,000 for lung cancer research and treatment.

Together, we can change the future of lung cancer care.

Donate here >

TOGA Announces Recipients of the 2026 Inspirational Research Grants - TOGA - Thoracic Oncology Group Australasia The Thoracic Oncology Group of Australasia (TOGA) is thrilled to announce the recipients of the 2026 Inspirational Research Grants.

What a week it has been for the ALK+community in Australia. Not one but TWO grants awarded this week that focus on advancing research in ALK Positive lung cancer. Go Science!
thoraciconcology.org.au/inspirationa...

We could not be more thrilled with these announcements today - empowering researchers with the resources they need to make a real difference to our community. Bravo to all involved!

Identifying ALK+ resistance pathways is at the very core of what is important to us all. That makes the announcement of Dr Vassiliadis as the recipient of the ALK Positive Australia/TOGA Inspirational Grant for 2026 so thrilling.
Every $ donated to ALK Positive Australia goes towards research.

YouTube video by ALKPositive Experts Ms Roxanne Chen - Understanding anaplastic lymphoma kinase (ALK).....

An excellent presentation for those of you interested in the science behind this disease & the way we move forward with treatment. A must watch, and delivered in a very approachable way. Thanks you Ms Chen and@alkpositiveuk.bsky.social @florianmerkle.bsky.social
youtu.be/ZlYnuuvLWuE?...

November is Lung Cancer Awareness Month, a time to elevate patient voices. Please consider sharing your story. alkpositive.org.au/2025/11/05/l...

#Lungcancer can affect anyone - even if it’s the last thing you’d expect. It doesn’t care about age, history or lifestyle.

Symptoms aren’t always obvious they can be subtle & not always respiratory related.

Don’t ignore signs that persist. Finding it early increases your options. #LCSM

Buy your @laces4lungs today! Bling up your shoes whilst supporting ALK Positive Australia & standing with us for Lung Cancer Awareness month. Buy your Laces4Lungs today!
ORDER HERE: docs.google.com/forms/d/e/1F...

ALK Positive Australia have released their inaugural newsletter! It is jam-packed with ALK+ news & achievements. If you are interested in receiving a copy please sign up here: alkpositive.org.au/membership-a...

Lung cancer is the leading cause of cancer death in Australia but receives less than 6% of the research funding. 35% of women & 15% of men diagnosed with lung cancer have never smoked. Help us drive research this November: alkpositive.org.au/donate/

ALK+ community please follow Laces4Lungs and throw your support behind this wonderful initiative, with all proceeds going to ALK+ Australia.
Well done AJ - you are a star!⭐️⭐️⭐️⭐️⭐️

www.facebook.com/profile.php?...

Our website got a glow-up!
Launching in the next few days — same mission, fresh new look.

Got feedback or ideas? Drop us a message here or email secretary@alkpositive.org.au

Sending deep gratitude & support from Down Under.

"WHAT IS IT REALLY LIKE TO LIVE WITH ALK ON TKI'S IN AUSTRALIA?"
Share your story in this important study. This is open to any Australian ALKie at Stage IIIB or IV on a TKI for more than 12 months. It will be an online interview for 30-60 minutes.
Email alkpositive@sjog.org.au to share your story.

- 36 Australians are diagnosed with lung cancer every day.
- Lung cancer is the leading cause of cancer death in Australia, but attracts less than 6% of cancer research funding.

Today we acknowledge those raising awareness & working towards better outcomes for lung cancer patients.

Our Chair Jon & Dep Chair Lisa with Prof Nick Pavlakis, Prof Ben Solomon & Prof Tom John at the @togaanz.bsky.social ASM - working together for better outcomes for ALK Positive patients.

We could not be prouder of our Dep Chair & friend Lisa Briggs - the recently announced recipient of the 2025 Jeannie Ferris Award. Bravo Lisa - thank you for all that you do. You are a force!

YouTube video by ALK Positive Australia The ALK Positive Australia & TOGA Inspirational Research Grant applications are now open!

The TOGA/ALK Positive Australia Inspirational Grant applications are now open! youtu.be/DzZBR6DPAN8?...

🤝 Eligibility: Projects must involve consumer representatives.

Get ready to apply and make an impact!

Let’s work together to drive real change.

Find out more > buff.ly/2Tv3YUR

The ALK+ Australia & TOGA Inspirational Research Grant applications are now open! We are proudly seeking innovative research that makes a real difference for people living with ALK-positive lung cancer. thoraciconcology.org.au/inspirationa...

YouTube video by ALK Positive Inc. Break Through Cancer on ALKtALK 6/1/25: updates on ALK vaccine & targeting minimal residual disease

This recent presentation on the ALK+ vaccine & current research being undertaken in the US is truly a MUST WATCH. It brings true hope. Thank you to everyone involved, we are cheering you on from Down Under!
youtu.be/GxrUsGIAFUs?...

ALK+ Community - many businesses make notable donations to charities at this time of year, for tax benefits & to demonstrate corporate social responsibility. If you know a decision maker in a the corporate world please put forward our charity for their consideration. More Research = More Life.

A wonderful, inspiring initiative that provides the entire ALK+ world with hope. Thank you!

CALLING RESEARCHERS! The ALK Positive Australia & TOGA Inspirational Research Grant for ALK+ NSCLC is back. We are seeking innovative research that makes a real difference for people living with ALK-positive lung cancer.

Now is the time to prepare a proposal. Further information coming soon.

One of our favourite days of the year. Go Research!

The article titled "Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial" presents findings from a clinical study evaluating the efficacy and safety of combining alectinib, an ALK tyrosine kinase inhibitor, with bevacizumab, an anti-angiogenic agent, in treating advanced ALK-rearranged non-small cell lung cancer (NSCLC). Nature Here are five key takeaways from the study: Enhanced Progression-Free Survival (PFS): The combination therapy achieved a 12-month PFS rate of 97.1% and a 36-month PFS rate of 64.2%, indicating a potential improvement over historical data for alectinib monotherapy. Nature High Overall Response Rate (ORR): All 41 patients in the study responded to the treatment, with 87.8% achieving partial responses and 12.2% achieving complete responses, resulting in a 100% ORR. Nature Intracranial Efficacy: The therapy demonstrated significant activity in the central nervous system, with a 36-month intracranial PFS rate of 87.8%, suggesting effectiveness in preventing or delaying brain metastases. Nature Manageable Safety Profile: While 46.3% of patients experienced grade 3–4 adverse events, including proteinuria and hepatotoxicity, no fatal events were reported, and quality of life improved over the course of treatment. Nature Need for Further Research: The promising results support the rationale for conducting randomized controlled trials to compare this combination therapy directly with existing standard treatments and to further assess its benefits and risks. Nature These findings suggest that the combination of alectinib and bevacizumab may offer a potent first-line treatment option for patients with advanced ALK-rearranged NSCLC, warranting further investigation in larger, randomized studies

Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong.

Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer

🎙️ Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy

Join Prof Tom John, Prof Ken O'Byrne and special guest Prof Georgina Long AO as they delve into technological advances spurred by COVID-19 vaccine development, promising results from recent melanoma and lung cancer vaccine trials

YouTube video by ALK Positive Australia ALK Positive advocating for molecular testing for all lung cancer patients.

Our Chairperson Jon advocating for molecular testing for all lung cancer patients on the national news, and raising awareness for ALK Positive lung cancer. youtu.be/eoAT1mDrKnM